We recently reiterated a Neutral recommendation on The Medicines Company (MDCO), which carries a Zacks #3 Rank (short-term Hold rating). The Medicines Company reported a first-quarter profit of 60 cents per share, well above the Zacks Consensus Estimate of 39 cents and the year-ago profit of 19 cents. Performance was boosted by higher revenues. Revenues, [...] (MDCO) The Medicines Company Analyst Reiterates Neutral on Shares